Statistical Analysis of Pulmonary Mycosis in a Tertiary Hospital in Eastern China before and after the Pandemic of COVID-19.

IF 2.3 3区医学 Q3 INFECTIOUS DISEASES

Medical mycology Pub Date : 2025-07-02 DOI:10.1093/mmy/myaf058

Gege Cao, Ran Wang, Qingtian Hu, Yong Zhang, Desheng Wu

{"title":"Statistical Analysis of Pulmonary Mycosis in a Tertiary Hospital in Eastern China before and after the Pandemic of COVID-19.","authors":"Gege Cao, Ran Wang, Qingtian Hu, Yong Zhang, Desheng Wu","doi":"10.1093/mmy/myaf058","DOIUrl":null,"url":null,"abstract":"<p><p>Following the complete relaxation of Corona Virus Disease 2019 (COVID-19) epidemic control measures in China by the end of 2022, the number of patients with pulmonary mycosis admitted to hospitals across the country has exhibited a more pronounced upward trend. However, statistical data is lacking to determine whether there is a significant correlation between COVID-19 and pulmonary mycosis. This study collected baseline information, the first laboratory indicators after admission, the types of pathogens, and the prognosis data of patients with pulmonary fungal infections from a tertiary hospital in northern Anhui Province from January 1, 2017, to December 31, 2023, to reveal any association between COVID-19 infection and pulmonary fungal infections. The research results indicated that the G and GM test levels of patients who recovered from COVID-19 and those currently experiencing active infection with COVID-19 were significantly higher than those of patients with pulmonary fungal infections who had never been infected with COVID-19. Infection with COVID-19 and other viruses (excluding COVID-19), mechanical ventilation, and concurrent solid tumors were identified as independent risk factors for poor prognosis in patients with pulmonary fungal diseases. Among patients with viral infections, COVID-19 infection was the most common, with 25 cases (41.67%), followed by herpes simplex virus infection, with 15 cases (25.00%).</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myaf058","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Following the complete relaxation of Corona Virus Disease 2019 (COVID-19) epidemic control measures in China by the end of 2022, the number of patients with pulmonary mycosis admitted to hospitals across the country has exhibited a more pronounced upward trend. However, statistical data is lacking to determine whether there is a significant correlation between COVID-19 and pulmonary mycosis. This study collected baseline information, the first laboratory indicators after admission, the types of pathogens, and the prognosis data of patients with pulmonary fungal infections from a tertiary hospital in northern Anhui Province from January 1, 2017, to December 31, 2023, to reveal any association between COVID-19 infection and pulmonary fungal infections. The research results indicated that the G and GM test levels of patients who recovered from COVID-19 and those currently experiencing active infection with COVID-19 were significantly higher than those of patients with pulmonary fungal infections who had never been infected with COVID-19. Infection with COVID-19 and other viruses (excluding COVID-19), mechanical ventilation, and concurrent solid tumors were identified as independent risk factors for poor prognosis in patients with pulmonary fungal diseases. Among patients with viral infections, COVID-19 infection was the most common, with 25 cases (41.67%), followed by herpes simplex virus infection, with 15 cases (25.00%).

查看原文本刊更多论文

2019冠状病毒病大流行前后华东地区某三级医院肺真菌病统计分析

随着2022年底中国疫情防控措施全面放松，全国住院肺真菌病患者数量呈现更加明显的上升趋势。然而，缺乏统计数据来确定COVID-19与肺真菌病之间是否存在显著相关性。本研究收集2017年1月1日至2023年12月31日皖北某三级医院肺部真菌感染患者的基线信息、入院后首次实验室指标、病原体类型和预后数据，以揭示COVID-19感染与肺部真菌感染之间的关联。研究结果表明，新冠肺炎恢复期患者和目前正在经历新冠肺炎活动性感染的患者的G和GM检测水平明显高于从未感染过新冠肺炎的肺部真菌感染患者。发现肺部真菌性疾病患者感染COVID-19及其他病毒（不包括COVID-19）、机械通气、并发实体瘤为预后不良的独立危险因素。病毒感染中以COVID-19感染最多，25例（41.67%），其次是单纯疱疹病毒感染，15例（25.00%）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.